U.S. health start-ups profiting from shortages of popular anti-obesity drugs are facing questions over the sustainability of their new revenue streams, Oliver Barnes of The Financial Times reports. Telehealth companies, such as Hims & Hers (HIMS), have cornered the market in cheaper alternatives to mainstream jabs, serving customers unable to get their hands on originals, such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound. U.S. law stipulates copycat drugs can only be manufactured in bulk when the branded originals are officially designated as being in short supply.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Viking Therapeutics selloff on Zepbound news an opportunity, says Truist
- Him & Hers tumbles as Lilly slashes prices on lowest doses of weight loss drug
- Morning Movers: Paramount slides as Bronfman drops bid
- Citi says Lilly Zepbound offering ‘shot across the bow’ for compounders
- Hims & Hers slips after Lilly says discount Zepbound single-dose vials available